Low PE Multibagger Research Pharma Stock Rallies 32% in a Month; Check Key Growth Triggers

On Wednesday, Indian equity benchmarks traded sharply lower, with the benchmark Nifty 50 index declining 2.12 per cent to 23,882.05. Amid the broader market weakness, Sun Pharma Advanced Research Company (SPARC) share price traded at Rs 270, up 1.37 per cent from the previous close.

Stock Delivers Strong Returns Across Timeframes

SPARC has witnessed strong momentum in its share price over the past few months. The stock has generated 32.12 per cent returns in one month, while delivering 99.05 per cent returns over the last six months and 71.92 per cent returns over the past one year.

The company currently has a market capitalisation of Rs 8,843 crore. It trades at a price-to-earnings (PE) ratio of 5.66, significantly lower than the industry average PE of 35.

Here Are the Key Reasons Behind the Rally

Cost Optimisation: SPARC achieved annual fixed cost savings of around USD 10 million by reducing its workforce from over 400 employees to nearly 250 and consolidating its research facilities from four labs to two, improving operational efficiency.

Clinical Pipeline Progress: The company's SCD-153 candidate for alopecia areata advanced to Phase 1B trials after clearing safety reviews, while SBO-154 continues Phase 1 studies across the US, Australia and India, strengthening its oncology and immunology pipeline.

Potential Financial Catalyst: A US District Court ruled in SPARC's favour regarding a previously denied Pediatric Rare Disease Voucher (PRV). If finalised, the voucher could generate more than USD 100 million, providing a significant liquidity boost.

FII Stake Increases: Foreign institutional investors raised their stake to 2.48 per cent in May 2026 from 2.04 per cent in March 2026. During the same period, promoter holding remained stable at around 65.68 per cent, while public shareholding increased and DII holding declined.
Also Read - Highest-Ever Dividend: Pharma Stock Sets July 9 Record Date for Rs 24 Final Dividend; Check Details

About Sun Pharma Advanced Research Company

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative pharmaceutical products. The company focuses on specialty therapies across oncology and immunology through proprietary research and global clinical development.

What are your thoughts on SPARC's clinical pipeline and recent share price performance? Share your views in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.